168 related articles for article (PubMed ID: 9602687)
1. Differential expression of CD44v6 in metastases of intestinal and diffuse types of gastric carcinoma.
Castellà EM; Ariza A; Pellicer I; Fernández-Vasalo A; Ojanguren I
J Clin Pathol; 1998 Feb; 51(2):134-7. PubMed ID: 9602687
[TBL] [Abstract][Full Text] [Related]
2. Expression of CD44 and its clinical implication in diffuse-type and intestinal-type gastric adenocarcinomas.
Hong RL; Lee WJ; Shun CT; Chu JS; Chen YC
Oncology; 1995; 52(4):334-9. PubMed ID: 7539903
[TBL] [Abstract][Full Text] [Related]
3. Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer.
Liu YJ; Yan PS; Li J; Jia JF
World J Gastroenterol; 2005 Nov; 11(42):6601-6. PubMed ID: 16425351
[TBL] [Abstract][Full Text] [Related]
4. Expression of E-cadherin, beta-catenin, CD44s and CD44v6 in gastric adenocarcinoma: relationship with lymph node metastasis.
Joo M; Lee HK; Kang YK
Anticancer Res; 2003; 23(2B):1581-8. PubMed ID: 12820426
[TBL] [Abstract][Full Text] [Related]
5. [Expression tumor stem cell surface marker CD44 in gastric cancer and its significance].
Xie JW; Huang CM; Zheng CH; Li P; Wang JB; Lin JX; Lu J
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Nov; 16(11):1107-12. PubMed ID: 24277411
[TBL] [Abstract][Full Text] [Related]
6. [Expression and clinical significance of CD44v6 and sCD44v6 in gastric carcinoma].
Zhou DH; Ma ZM; Chen Y
Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):833-7. PubMed ID: 18396641
[TBL] [Abstract][Full Text] [Related]
7. Importance of different CD44v6 expression in human gastric intestinal and diffuse type cancers for metastatic lymphogenic spreading.
Dämmrich J; Vollmers HP; Heider KH; Müller-Hermelink HK
J Mol Med (Berl); 1995 Aug; 73(8):395-401. PubMed ID: 8528741
[TBL] [Abstract][Full Text] [Related]
8. CD44 variant overexpression in gallbladder carcinoma associated with tumor dedifferentiation.
Yanagisawa N; Mikami T; Mitomi H; Saegusa M; Koike M; Okayasu I
Cancer; 2001 Jan; 91(2):408-16. PubMed ID: 11180088
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas.
Berner HS; Suo Z; Risberg B; Villman K; Karlsson MG; Nesland JM
Histopathology; 2003 Jun; 42(6):546-54. PubMed ID: 12786890
[TBL] [Abstract][Full Text] [Related]
10. Expression of CD44s and CD44v6 in lung cancer and their correlation with prognostic factors.
Afify AM; Tate S; Durbin-Johnson B; Rocke DM; Konia T
Int J Biol Markers; 2011; 26(1):50-7. PubMed ID: 21279958
[TBL] [Abstract][Full Text] [Related]
11. CD44V6 expression in human colorectal carcinoma.
Coppola D; Hyacinthe M; Fu L; Cantor AB; Karl R; Marcet J; Cooper DL; Nicosia SV; Cooper HS
Hum Pathol; 1998 Jun; 29(6):627-35. PubMed ID: 9635685
[TBL] [Abstract][Full Text] [Related]
12. [Expression of standard and variant CD44 in human lung cancer].
Zhao H; Fang J; Du G
Zhonghua Jie He He Hu Xi Za Zhi; 1998 Sep; 21(9):541-3. PubMed ID: 11360506
[TBL] [Abstract][Full Text] [Related]
13. Expression and prognostic value of the CD44 splicing variants v5 and v6 in gastric cancer.
Müller W; Schneiders A; Heider KH; Meier S; Hommel G; Gabbert HE
J Pathol; 1997 Oct; 183(2):222-7. PubMed ID: 9390037
[TBL] [Abstract][Full Text] [Related]
14. Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma.
Saito H; Tsujitani S; Katano K; Ikeguchi M; Maeta M; Kaibara N
Cancer; 1998 Sep; 83(6):1094-101. PubMed ID: 9740073
[TBL] [Abstract][Full Text] [Related]
15. CD44 loss in gastric stromal tumors as a prognostic marker.
Montgomery E; Abraham SC; Fisher C; Deasel MR; Amr SS; Sheikh SS; House M; Lilliemoe K; Choti M; Brock M; Ephron DT; Zahuruk M; Chadburn A
Am J Surg Pathol; 2004 Feb; 28(2):168-77. PubMed ID: 15043305
[TBL] [Abstract][Full Text] [Related]
16. Preferential overexpression of CD44v5 in advanced gastric carcinoma Goseki grades I and III.
Stachura J; Krzeszowiak A; Popiela T; Urbańczyk K; Pituch-Noworolska A; Wieckiewicz J; Zembala M
Pol J Pathol; 1999; 50(3):155-61. PubMed ID: 10624117
[TBL] [Abstract][Full Text] [Related]
17. CD44V6 in gastric carcinoma: a marker of tumor progression.
Xin Y; Grace A; Gallagher MM; Curran BT; Leader MB; Kay EW
Appl Immunohistochem Mol Morphol; 2001 Jun; 9(2):138-42. PubMed ID: 11396631
[TBL] [Abstract][Full Text] [Related]
18. Decreased expression of CD44 splicing variants in advanced colorectal carcinomas.
Weg-Remers S; Anders M; von Lampe B; Riecken EO; Schüder G; Feifel G; Zeitz M; Stallmach A
Eur J Cancer; 1998 Sep; 34(10):1607-11. PubMed ID: 9893637
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of CD44v6 mRNA significantly correlates with distant metastasis and poor prognosis in gastric cancer.
Yamamichi K; Uehara Y; Kitamura N; Nakane Y; Hioki K
Int J Cancer; 1998 Jun; 79(3):256-62. PubMed ID: 9645347
[TBL] [Abstract][Full Text] [Related]
20. Expression of CD44S and CD44v5 is more common in stage III than in stage I serous ovarian carcinomas.
Afify AM; Ferguson AW; Davila RM; Werness BA
Appl Immunohistochem Mol Morphol; 2001 Dec; 9(4):309-14. PubMed ID: 11759056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
